Update on the Recommended use of Hepatitis A Vaccine

This statement serves as an update to previous statements and will provide the evidence used to determine the optimal timing of immunization with a HA containing vaccine by providing a review of the evidence on the immunogenicity and safety of HA vaccine when administered to infants from 6 to 12 months of age and making recommendations for the immunization of individuals in this age group; reviewing evidence pertaining to the administration of HA vaccine to individuals with non-malignant hematologic disorders; and reviewing evidence pertaining to post exposure prophylaxis (PEP) in individuals with chronic liver disease and adults over 50 years of age.